This study, published in Scientific Reports, investigates whether low-dose aspirin (LDA) can safely improve pregnancy outcomes for a specific high-risk group: mothers carrying twins conceived via Assisted Reproductive Technology (ART). While LDA is a staple for preventing preeclampsia in singleton pregnancies, its efficacy and safety in the "precious" and complex context of ART twin pregnancies have remained unclear until now.
TL;DR
Low-dose aspirin (100 mg/day) significantly reduces the risk of preeclampsia in ART twin pregnancies without increasing the risk of postpartum bleeding. However, its protective benefits appear to diminish significantly in mothers over the age of 30 and do not extend to twin-specific complications like Twin-to-Twin Transfusion Syndrome (TTTS).
What Problem Does This Paper Address?
Twin pregnancies conceived through ART are on the rise and carry substantially higher risks of complications, including preterm labor, gestational hypertension, and fetal growth restriction. Because these pregnancies are often the result of long, difficult, and expensive journeys for parents, finding safe pharmacological interventions to improve outcomes is a clinical priority.
While the medical community generally agrees that LDA helps prevent preeclampsia in singletons by improving placental blood flow and reducing inflammation, data on ART twins is sparse. Clinicians face a dilemma: does the benefit of LDA outweigh the potential risk of increased maternal bleeding in these complex cases?
Methods
The researchers conducted a retrospective cohort study at a tertiary hospital in Chongqing, China, analyzing data from 665 ART twin pregnancies between 2016 and 2021. After exclusions (such as loss to follow-up), they focused on 510 pregnancies: 253 in the LDA group and 257 in the control group.
- Intervention: The LDA group received 100 mg/day starting between 10–16 weeks of gestation.
- Analysis: The team compared maternal complications (preeclampsia, gestational diabetes, etc.), neonatal outcomes (birth weight, NICU admission), and safety metrics (postpartum hemorrhage, ICU transfer). They also performed age-stratified analysis to see if maternal age influenced LDA effectiveness.
Datasets
The study utilized a hospital-based dataset of electronic standardized prenatal, delivery, and neonatal records.
- Total analyzed: 510 pregnancies.
- Composition: 476 dichorionic (DC) twins and 34 monochorionic (MC) twins.
- Conception: 500 IVF-ET (In Vitro Fertilization-Embryo Transfer) and 10 IUI (Intrauterine Insemination).
Key Insights and Ideas
- The Age Threshold: One of the most striking findings was that LDA’s protective effect against adverse outcomes was most pronounced in mothers under 30. In older mothers, the absolute risk of pregnancy complications—driven by age as an independent factor—seemed to bypass the benefits provided by aspirin.
- Safety Confirmation: A major hurdle for prescribing aspirin in pregnancy is the fear of hemorrhage. This study found no significant difference in postpartum bleeding volume or the need for blood transfusions between the LDA and control groups, suggesting 100 mg/day is a safe dosage for this population.
- Mechanism Specificity: LDA was effective against preeclampsia (a systemic vascular/inflammatory issue) but failed to prevent twin-specific "idiopathic" disorders like TTTS or TRAP (Twin Reverse Arterial Perfusion). This suggests these complications are driven by unique placental angioarchitecture that aspirin cannot modify.
- C-Section Reduction: Interestingly, the LDA group had a lower rate of Cesarean sections (p=0.045), though the authors suggest this may be a secondary benefit of reduced preeclampsia incidence.
Key Results
- Preeclampsia: LDA significantly lowered the incidence of preeclampsia compared to the control group (p < 0.05).
- Bleeding Risk: No statistical difference was found in postpartum hemorrhage (p=0.801) or 24-hour bleeding volume (p=0.0754).
- Neonatal Outcomes: There were no significant differences in mean birth weight (p=0.775) or NICU admission rates (p=0.768) between the two groups.
- Prevalence Trend: The study noted a sharp increase in LDA prescriptions over the 6-year period (from 22.2% in 2016 to 64% in 2021), reflecting a shift in clinical practice even before definitive evidence was available.
Limitations and Future Work
The authors acknowledge several limitations:
- Retrospective Design: As an observational study, it is subject to "confounding by indication"—for instance, the LDA group actually had higher rates of overall hypertensive disorders, likely because clinicians were more likely to prescribe aspirin to patients they already perceived as high-risk.
- Sample Size: The number of monochorionic twins (which carry higher risks) was relatively small, limiting the ability to draw specific conclusions for that subgroup.
- Single-Center Study: The findings are based on a specific population in China; multi-center, prospective randomized controlled trials (RCTs) are needed to confirm these results across different ethnicities and healthcare systems.
The researchers conclude that while LDA is a valuable tool for preeclampsia prevention in ART twins, clinicians should not "blindly" prescribe it to all patients, particularly older mothers where the benefits are less clear.
Summary updated